StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck nuvaRing (etonogestrel/ethinyl estradiol, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, Q1 2021
21
Period ended Mar 31, 2021
Change on a year earlier
-19.2%
26 in Q1 2020
History
18 quarters
Since Q4 2016
Sources
14
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNuvaRing (etonogestrel/ethinyl estradiol, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)Year on yearSource
Q1 2021Mar 31, 202121-19.2%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2020Dec 31, 202025-83.3%Form 10-K (filed 2021-02-25) ↗
Q3 2020Sep 30, 202024-88.1%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 202035-83.0%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 202026-85.9%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2019Dec 31, 2019150-12.3%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 2019202+4.7%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2019Jun 30, 2019206+10.2%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2019Mar 31, 2019185+8.2%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2018Dec 31, 2018171+23.0%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2018Sep 30, 2018193+20.6%Form 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗
Q2 2018Jun 30, 2018187+22.2%Form 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗
Q1 2018Mar 31, 2018171+51.3%Form 8-K (a19-8996_1ex99d1.htm, filed 2019-04-30) ↗
Q4 2017Dec 31, 2017139-10.3%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2017Sep 30, 2017160–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2017Jun 30, 2017153–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗

Breakdown

What makes up nuvaring (etonogestrel/ethinyl estradiol, legacy pre-organon spin-off) — u.s. sales ($m)

Cite this data

StockData. (2026). Merck NuvaRing (etonogestrel/ethinyl estradiol, legacy pre-Organon spin-off) — U.S. sales ($M) ($M), quarterly Q4 2016–Q1 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_nuvaring_us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.